Back to today’s briefing

Story perspectives

New Drug Combo Boosts Survival in Breast Cancer Trial

4/21/2025

32 7

Summary

Story summary

A groundbreaking trial, DESTINY-Breast09, revealed that pairing ENHERTU with pertuzumab dramatically enhances progression-free survival for patients battling HER2-positive metastatic breast cancer, outshining the traditional THP regimen. With early survival data looking hopeful, AstraZeneca and Daiichi Sankyo are set to seek regulatory approval, signaling a potential revolution in first-line treatment.

1 of 1

Story summary

A groundbreaking trial, DESTINY-Breast09, revealed that pairing ENHERTU with pertuzumab dramatically enhances progression-free survival for patients battling HER2-positive metastatic breast cancer, outshining the traditional THP regimen. With early survival data looking hopeful, AstraZeneca and Daiichi Sankyo are set to seek regulatory approval, signaling a potential revolution in first-line treatment.